Trial Outcomes & Findings for Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction. (NCT NCT02836899)

NCT ID: NCT02836899

Last Updated: 2026-03-10

Results Overview

Acute kidney injury (AKI) is defined by KDIGO criteria as an abrupt (within 48h) reduction in kidney function correlated to an absolute increase in serum creatinine of 0.3 mg/dL or more (≥26.4 μmol/L) or a percentage increase in serum creatinine of 50% or more (1.5-fold from baseline) at any time during the first 7 days after surgery or, finally, a reduction in urine output with a documented oliguria of \< 0.5 ml/Kg/h for \>6h.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

250 participants

Primary outcome timeframe

7 days

Results posted on

2026-03-10

Participant Flow

Participant milestones

Participant milestones
Measure
Control
Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. Placebo: This is the placebo group. Nitrogen will be added instead of nitric oxide.
Nitric Oxide
Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours. Nitric Oxide: Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
Overall Study
STARTED
125
125
Overall Study
COMPLETED
125
125
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Control
n=125 Participants
Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. Placebo: This is the placebo group. Nitrogen will be added instead of nitric oxide.
Nitric Oxide
n=125 Participants
Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours. Nitric Oxide: Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
Total
n=250 Participants
Total of all reporting groups
Region of Enrollment
United States
125 participants
n=68 Participants
125 participants
n=69 Participants
250 participants
n=137 Participants
BMI
28.3 kg/m^2
n=68 Participants
28.9 kg/m^2
n=69 Participants
28.6 kg/m^2
n=137 Participants
Age, Continuous
66 years
n=68 Participants
66 years
n=69 Participants
66 years
n=137 Participants
Sex: Female, Male
Female
30 Participants
n=68 Participants
26 Participants
n=69 Participants
56 Participants
n=137 Participants
Sex: Female, Male
Male
95 Participants
n=68 Participants
99 Participants
n=69 Participants
194 Participants
n=137 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
Race (NIH/OMB)
Asian
2 Participants
n=68 Participants
3 Participants
n=69 Participants
5 Participants
n=137 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=68 Participants
2 Participants
n=69 Participants
4 Participants
n=137 Participants
Race (NIH/OMB)
White
121 Participants
n=68 Participants
120 Participants
n=69 Participants
241 Participants
n=137 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
ASA Grade
2
3 Participants
n=68 Participants
7 Participants
n=69 Participants
10 Participants
n=137 Participants
ASA Grade
3
94 Participants
n=68 Participants
94 Participants
n=69 Participants
188 Participants
n=137 Participants
ASA Grade
4
28 Participants
n=68 Participants
24 Participants
n=69 Participants
52 Participants
n=137 Participants
NYHA Classification Score
I
45 Participants
n=68 Participants
38 Participants
n=69 Participants
83 Participants
n=137 Participants
NYHA Classification Score
II
64 Participants
n=68 Participants
60 Participants
n=69 Participants
124 Participants
n=137 Participants
NYHA Classification Score
III-IV
16 Participants
n=68 Participants
27 Participants
n=69 Participants
43 Participants
n=137 Participants

PRIMARY outcome

Timeframe: 7 days

Acute kidney injury (AKI) is defined by KDIGO criteria as an abrupt (within 48h) reduction in kidney function correlated to an absolute increase in serum creatinine of 0.3 mg/dL or more (≥26.4 μmol/L) or a percentage increase in serum creatinine of 50% or more (1.5-fold from baseline) at any time during the first 7 days after surgery or, finally, a reduction in urine output with a documented oliguria of \< 0.5 ml/Kg/h for \>6h.

Outcome measures

Outcome measures
Measure
Placebo Comparator: Control
n=125 Participants
Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
Experimental: Nitric Oxide
n=125 Participants
Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
Number of Participants With Acute Kidney Injury
54 Participants
55 Participants

SECONDARY outcome

Timeframe: 7 days after cardiac surgery

Difference in AKI severity between the two groups using following KDIGO stages.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: up to 1 year

To study the incidence of acute renal failure requiring RRT

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 weeks after cardiac surgery

Difference between groups of MAKE at 6 weeks after surgery. MAKE is a composite outcome of death, new dialysis and worsened renal function (defined as a 25% or greater decline in eGFR compared to the baseline).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 7 days

Assessment of organ dysfunction through the evaluation of SOFA score

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 48 hours after cardiac surgery

Difference between groups of prolonged cardiovascular support defined as need for vasopressors, inotropic agents, balloon pump, or ventricular-assist device for more than 48 hours after cardiac surgery.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 7 days after cardiac surgery

Difference between groups of maximum daily VIS and duration of vasopressors and or inotropic agents support. VIS is calculated as Dopamine dose (mcg/kg/min) + Dobutamine dose (mcg/kg/min) + 100 x Epinephrine dose (mcg/kg/min) + 10 x Milrinone dose (mcg/kg/min) + 10,000 x Vasopressin dose (units/kg/min) + 100 x Norepinephrine dose (mcg/kg/min) + 10 x Phenilephrine dose (mcg/kg/min).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: up to 6 weeks

Difference of duration of mechanical ventilation

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: up to 6 weeks

Difference between groups of ICU-LOS defined as number of days spent in an ICU bed.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: up to 1 year

Difference between groups of hospital LOS defined as number of days spent in a hospital bed.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 6 weeks

Renal biomarkers to evaluate renal tubular injury.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 7 days

Incidence and severity of AKI related to presence of CKD at baseline, duration of CPB, duration of aortic cross clamp, levels of free Hb, levels of NO consumption, pulmonary pressure at baseline, cardiovascular risks associated with endothelial dysfunction, scheduled procedure and EuroSCORE II.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 7 days after cardiac surgery

Difference between groups of Incidence of Delirium will be assessed daily in the first 7 days after surgery by using the confusion assessment method for intensive care unit (CAM-ICU).

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: One year follow up

Analysis of the quality of life up to 1 year after surgery by the Activity of Daily Living evaluation (by Katz Index) and PROMIS global health.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: up to 1 year

Evaluation of the overall intrahospital mortality and at 28 6 weeks 90 days and 1 year after surgery

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: During and 48 hours after cardiac surgery

Blood methemoglobin levels will be measured to evaluate the oxidation of oxyhemoglobin in the two groups until 48h after surgery.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 6 weeks

Difference between groups of incidence of non fatal stroke will be assessed by at 6 weeks after cardiac surgery.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 72 hours and 1 year follow up

Incidence of Perioperative and non-perioperative nonfatal myocardial infarction as defined by the third universal definition of MI released in 2012 by the ESC/ACCF/AHA/WHF.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 24 after surgery

Incidence of postoperative bleeding calculated as the sum of blood loss through thoracic drains from the moment of closure of the chest over a period of 24 hours.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 7 days surgery

Differences between the two groups of transfusions with plasma and stored or autologous red blood cells (RBCs) recovered using intraoperative cell salvage devices.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 6 weeks

Post-operative infections (e.g., pneumonia, wound infection, endocarditis, central line infection, urinary tract infection, sepsis).

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 6 weeks

Cardiac arrhythmias and other non-cardiac post-operative complications (e.g., hepatobiliary disorders, pneumothorax, pleural effusion, vascular disorders).

Outcome measures

Outcome data not reported

Adverse Events

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Nitric Oxide

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Lorenzo Berra, MD

Massachusetts General Hospital

Phone: 617-726-3030

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place